Physician profile
Shivan Tekwani
NPI 1518122035
$24,584.20
in general payments reported to CMS, 2019-2025
21 companies · $773 in 2025
The $773 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $108 · 2021: $2,426 · 2022: $150 · 2023: $751 · 2024: $5,683 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Food and Beverage: $2,407 · Consulting Fee: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Food and Beverage | $2,407.23 |
| Consulting Fee | $1,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,196.29 | 2019-2021 | |
| Alimera Sciences, INC. | $6,769.82 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $6,294.71 | 2021-2025 | Lumigan, Ozurdex, Alphagan P |
| Regeneron Healthcare Solutions, INC. | $603.55 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $509.31 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Astellas Pharma US INC | $304.52 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $170.46 | 2023-2025 | Syfovre |
| Eyepoint US, INC. | $137.59 | 2024 | |
| Sight Sciences, INC. | $94.02 | 2021-2024 | Omni Surgical System |
| Amgen INC. | $90.84 | 2025 | Tepezza, Pavblu |
| Ani Pharmaceuticals, INC. | $83.17 | 2025 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $74.22 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $65.87 | 2023-2025 | Xipere, Envista Envy Iol, Envista Mx60 Iol |
| Genentech USA, INC. | $35.91 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $28.35 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $27.82 | 2025 | Oxervate |
| Genentech, INC. | $26.30 | 2022 | |
| Rxsight INC | $23.97 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.10 | 2023 | Acthar |
| Lensar, INC. | $13.14 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivan Tekwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.